Contact Us
Know more about PrEP Patients to consider Eligibility for PrEP Quest HIV PrEP solution

Make PrEP a step in your HIV prevention efforts—with help from Quest Diagnostics

For those patients at risk for HIV infection, the Centers for Disease Control and Prevention (CDC) and United States Preventative Services Task Force (USPSTF) recommend HIV pre-exposure prophylaxis, or PrEP. Quest Diagnostics is the first national laboratory to commercially offer HIV PrEP Panel, which includes all CDC-recommended tests, clearing the way for PrEP.

Q&A: PrEP Panel to improve testing process

Hear from Dr Gina Simoncini, deputy director of the Comprehensive HIV Program at Lewis Katz School of Medicine at Temple University, and Dr Meghan Starolis, infectious disease specialist at Quest Diagnostics, as they discuss how PrEP has affected the rate of HIV infection, what’s needed to begin treatment, and advances in baseline PrEP-related testing.

Know more about PrEP

PrEP is a daily pill (tenofovir and emtricitabine) for patients who want to prevent HIV infection from exposure to the virus through sex or injection drug use.

  • Patients must commit to taking the drug every day and seeing their healthcare provider for follow-up every 3 months
  • Daily PrEP reduces the risk of getting HIV from sex by more than 90%, and from injection drug use by more than 70%1
  • A panel of laboratory tests must be performed prior to and during treatment
 
Read more
Read less

Know which patients to consider for testing

CDC guidelines outline which patients may benefit from PrEP-related testing and use, namely those who are HIV-negative and at risk for HIV infection.2 Some are included below.

  • Anyone without HIV who is at very high risk for getting it from sex or injection drug use2
  • Couples in which one partner is HIV-positive and the other is HIV-negative2
  • Anyone who is HIV-negative and self-identifies as at risk or doesn’t know the HIV status of their sexual partner(s)2
 
Read more
Read less

Determining clinical eligibility for PrEP

The CDC recommends a number of lab tests to determine a patient’s clinical eligibility for PrEP, some of which are listed below. Quest’s HIV PrEP Panel includes them all.2

  • Documented negative HIV screening test before prescribing PrEP and throughout treatment2
  • Normal renal function, no contraindicated medications2
  • Documented negative hepatitis B virus infection and vaccination status2
  • The patient must also present with no signs or symptoms of acute HIV infection2
 
Read more
Read less

Benefit from the Quest HIV PrEP solution

HIV PrEP Panel from Quest is the first available PrEP panel from a commercial lab, including baseline, monitoring, and supplemental tests.

  • Includes all CDC guideline-recommended tests needed to determine clinical eligibility for PrEP
  • Determines clinical eligibility with just one test code
  • Clears the way for PrEP treatment
 
Read more
Read less

Get the answers you need

HIV PrEP Panel from Quest includes all the CDC guideline-recommended tests you need in order to determine clinical eligibility for PrEP.2

Test Name

Test Code

Baseline

PrEP HIV Baseline, Male Panel with Reflexes HIV-1/2, renal function, HCV, HBV, syphilis, CT/NG

PrEP HIV Baseline, Female Panel with Reflexes HIV-1/2, hCG, renal function, HCV, HBV, syphilis, CT/NG

37106

37133

Monitoring

PrEP HIV Monitoring, Male Panel HIV-1/2, renal function, syphilis, CT/NG

PrEP HIV Monitoring, Female Panel HIV-1/2, hCG, renal function, syphilis, CT/NG

37136

37138

Supplemental and Individual Components

HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes

91431

hCG, Total, Quantitative

8396

Renal Function Panel

10314

Hepatitis C Antibody with Reflex to HCV RNA,PCR w/Reflex to Genotype, LiPA®

94345

Hepatitis B Surface Antigen with Reflex Confirmation

498

Hepatitis B Surface Antibody, Qualitative

499

Hepatitis B Core Antibody, Total, with Reflex to IgM

37676

RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing

36126

Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, Urogenital

11363*

Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, rectal

16506(X)*

Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, throat

70051(X)*

The CDC recommends that individuals at a higher risk for developing STIs are tested at appropriate anatomic sites of exposure, including urethral, rectal, and pharyngeal. Quest Diagnostics offers STI testing with collection devices that aligns with this recommendation.

Note: individual component tests of all panels listed above can be viewed in the Test Directory and may be ordered separately.

*The analytical performance characteristics of this assay, when used to test specimens collected with the multitest swab, unisex swab, and urine, have been determined by Quest Diagnostics.

HIV prevention is just one test code away.

Learn more about our HIV PrEP Panel.

 

Download flyer

 

Connect with us today, and a Quest sales representative will be in touch

References

  1. Centers for Disease Control and Prevention. PrEP 101. March 2018. www.cdc.gov/hiv/pdf/library/factsheets/prep101-consumer-info.pdf. Accessed January 17, 2019.
  2. Centers for Disease Control and Prevention. Pre-exposure prophylaxis (PrEP) for HIV prevention. Fact sheet. www.cdc.gov/hiv/pdf/PrEP_fact_sheet_final.pdf. Accessed January 17, 2019.
Terms of Use  |  Privacy Notices  |  Contact Us  |  QuestDiagnostics.com  | Privacy Shield | Your Privacy Choices

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved.